SCHEMBL24276764

SCHEMBL24276764

Cc1cc(-c2nn3c(c2N)C(C)N(C(=O)OC(C)(C)C)CC3)cc(C)c1F

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAP4K4 O95819 1/20 0.33
▸ LMNA P02545 1/20 0.32
▸ NPSR1 Q6W5P4 1/20 0.32
▸ NR1H2 P55055 3/20 0.32
▸ NR1H3 Q13133 2/20 0.32
▸ KAT7 O95251 2/20 0.32
▸ KAT8 Q9H7Z6 1/20 0.32
▸ ACACB O00763 2/20 0.31
▸ KAT6A Q92794 1/20 0.31
▸ CSNK1E P49674 1/20 0.31
▸ DPP4 P27487 2/20 0.31
▸ ALOX5AP P20292 1/20 0.31
▸ FEN1 P39748 1/20 0.31
▸ THRB P10828 1/20 0.31
▸ HDAC1 Q13547 3/20 0.31
▸ HDAC2 Q92769 2/20 0.31
▸ SETD7 Q8WTS6 1/20 0.30
▸ CYP1A2 P05177 1/20 0.30
▸ POLB P06746 1/20 0.30
▸ CYP3A4 P08684 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24276775 0.88 USP30 (0.33) LMNANPSR1NR1H2NR1H3KAT7
SCHEMBL29308625 0.87 CSNK1D (0.39) MAP4K4CSNK1EHDAC1HDAC2SETD7
SCHEMBL31692233 0.83 NPSR1 (0.35) LMNANPSR1NR1H2NR1H3KAT7
SCHEMBL31692539 0.82 KAT7 (0.35) MAP4K4LMNANPSR1NR1H2NR1H3
SCHEMBL24276770 0.81 GRM5 (0.36) LMNANPSR1NR1H2NR1H3KAT7
SCHEMBL24277086 0.80 CSNK1E (0.43) NR1H2CSNK1E
SCHEMBL26185733 0.80 KAT7 (0.34) LMNANPSR1NR1H2NR1H3KAT7
SCHEMBL24276763 0.80 LMNA (0.30) LMNANPSR1
SCHEMBL24276765 0.77 KAT7 (0.32) LMNANPSR1KAT7KAT8KAT6A
SCHEMBL31424448 0.77 NR1H2 (0.33) LMNANPSR1NR1H2NR1H3ACACB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12595264-B2 Heterocyclic GLP-1 agonists GASHERBRUM BIO, INC. (US) 2026-04-07 — — US disclosed
US-20230331732-A1 HETEROCYCLIC GLP-1 AGONISTS GASHERBRUM BIO, INC. 2023-10-19 — — US disclosed
US-20230331732-A1 HETEROCYCLIC GLP-1 AGONISTS GASHERBRUM BIO, INC. 2023-10-19 — — US disclosed
US-20230331732-A1 HETEROCYCLIC GLP-1 AGONISTS GASHERBRUM BIO, INC. 2023-10-19 — — US disclosed
EP-4211139-A1 HETEROCYCLIC GLP-1 AGONISTS Gasherbrum Bio, Inc. (US) 2023-07-19 — — EP disclosed
WO-2022052958-A1 HETEROCYCLIC GLP-1 AGONISTS GASHERBRUM BIO, INC. (US) 2022-03-17 — — WO disclosed
WO-2022052958-A1 HETEROCYCLIC GLP-1 AGONISTS GASHERBRUM BIO, INC. (US) 2022-03-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12595264-B2 Heterocyclic GLP-1 agonists GLP1R, GIPR, GCGR MAP4K4 4026/4885LMNA 2183/4885NPSR1 320/4885
US-20230331732-A1 HETEROCYCLIC GLP-1 AGONISTS GLP1R, GIPR, GCGR MAP4K4 2071/4885LMNA 3620/4885NPSR1 203/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback